Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis to assess the dose-effect relationship and determine the optimum dose.

开始日期2004-12-24

申办/合作机构

Bayer Australia Ltd.

EUCTR2004-002171-16-IT / Not yet recruitingN/A

Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study

开始日期2004-10-18

申办/合作机构

Bayer AG

100 项与 YG-001 相关的临床结果

登录后查看更多信息

100 项与 YG-001 相关的转化医学

登录后查看更多信息

100 项与 YG-001 相关的专利（医药）

登录后查看更多信息

2,744

项与 YG-001 相关的文献（医药）

2024-10-01·Cardiovascular drugs and therapy

Rivaroxaban in Valvular Atrial Fibrillation — a Critical Appraisal of the INVICTUS Trial

Article

作者: Sulzgruber, Patrick ; Niessner, Alexander ; Hammer, Andreas

Abstract:

Purpose:

The efficacy of factor Xa inhibitors in patients with atrial fibrillation (AF) and rheumatic heart disease (RHD) is unknown.

Methods/Results:

The objective of this article was to conduct a comprehensive evaluation of the INVICTUS trial, an open-label randomized controlled study that compared vitamin K antagonists (VKA) to rivaroxaban in patients with AF and RHD while also considering the existing evidence from literature in this particular area of research.

Conclusion:

The findings of the INVICTUS trial indicated that rivaroxaban was found to be inferior in efficacy to VKA. However, it is important to note that the primary outcome of the trial was driven by sudden death and death caused by mechanical pump failure. As a result, it is necessary to approach the data from this study with caution, and it would be inappropriate to draw parallel conclusions for other causes of valvular AF. Particularly, the perplexing issue of how rivaroxaban could have contributed to both pump failure and sudden cardiac death requires further explanation. Additional data regarding changes in heart failure medication and ventricular function would be essential for proper interpretation.

2024-09-01·Cardiology and Therapy

Is There an Alternative Oral Anticoagulation to Vitamin-K-Antagonists for Patients with Mechanical Aortic Valve Replacement? – A Literature Review

Review

作者: Wahlers, Thorsten ; Kuhn, Elmar ; Gerfer, Stephen

Current guidelines exclusively recommend vitamin-K-antagonists (VKA) as anticoagulation for patients after mechanical aortic valve replacement due to the increased postoperative risk of valve thrombosis and thrombo-embolism. Strict and regular assessments are mandatory during VKA therapy to ensure a potent anticoagulatory effect within the desired range. From the patients' perspective, VKA are associated with relevant interactions and side effects reducing the quality of life and contributing to a high number of patients not achieving the optimal therapeutic target. Direct oral anticoagulants (DOAC) have replaced VKA therapy in the past for several indications, e.g., atrial fibrillation. However, it is still unclear if DOACs could replace VKA therapy in patients after mechanical aortic valve replacement. While the PROACT-Xa study did not show a sufficient anticoagulatory effect of apixaban plus aspirin compared to VKA therapy in patients after mechanical aortic valve replacement, the direct thrombin inhibitor dabigatran and the oral factor Xa inhibitors apixaban and rivaroxaban showed promising results in comparable patient cohorts in smaller studies and case reports. Factor Xa inhibitors were able to prevent thrombosis and thrombo-embolic events in patients after mechanical aortic valve replacement. Therefore, factor Xa inhibitors or factor XI inhibitors could provide a potent alternative to VKA for patients after a mechanical aortic valve replacement.

2024-09-01·European stroke journal

Efficacy and safety of oral factor Xa inhibitors versus vitamin-K antagonists in the early phase after acute ischemic stroke or TIA in the real-world setting: The PRODAST study

Article

作者: Soda, Hassan ; Kraft, Peter ; Grosse, Gerrit M ; Diener, Hans-Christoph ; Stang, Andreas ; Hilker-Roggendorf, Rüdiger ; Hüsing, Anika ; Pohlmann, Carsten ; Kuklik, Nils ; Eschenfelder, Christoph C ; Maurer, Gabriele D ; Weimar, Christian ; Mackert, Bruno-Marcel ; Brinkmann, Marcus ; Popovic, Nikola

Introduction::

Factor Xa (FXa) inhibitors are superior to vitamin K antagonists (VKAs) in terms of avoiding hemorrhagic complications. However, no robust data are available to date as to whether this also applies to the early phase after stroke. In this prospective registry study, we aimed to investigate whether anticoagulation with FXa inhibitors in the early phase after acute ischemic stroke or transient ischemic attack (TIA) is associated with a lower risk of major bleeding events compared with VKAs.

Materials and methods::

The Prospective Record of the Use of Dabigatran in Patients with Acute Stroke or TIA (PRODAST) study is a prospective, multicenter, observational, post-authorization safety study at 86 German stroke units between July 2015 and November 2020. Primary outcome was a major bleeding event during hospital stay. Secondary endpoints were recurrent strokes, recurrent ischemic strokes, TIA, systemic/pulmonary embolism, myocardial infarction, death and the composite endpoint of stroke, systemic embolism, life-threatening bleeding and death.

Results::

In total, 10,039 patients have been recruited. 5,874 patients were treated with FXa inhibitors and 1,050 patients received VKAs and were eligible for this analysis. Overall, event rates were low. We observed 49 major bleeding complications during 33,297 treatment days with FXa-inhibitors (rate of 14.7 cases per 10,000 treatment days) and 16 cases during 7,714 treatment days with VKAs (rate of 20.7 events per 10,000 treatment days), translating into an adjusted hazard ratio (aHR) of 0.70 (95% confidence interval (95% CI): 0.37–1.32) in favor of FXa inhibitors. Hazards for ischemic endpoints (63 vs 17 strokes, aHR: 0.96 (95% CI: 0.53–1.74), mortality (33 vs 6 deaths, aHR: 0.87 (95% CI: 0.33–2.34)) and the combined endpoint (154 vs 39 events, aHR: 0.99 (95% CI: 0.65–1.41) were not substantially different.

Discussion and conclusion::

This large real-world study shows that FXa inhibitors appear to be similarly effective in terms of bleeding events and ischemic endpoints compared to VKAs in the early post-stroke phase of hospitalization. However, the results need to be interpreted with caution due to the low precision of the estimates.

项与 YG-001 相关的新闻（医药）

2024-05-13

·Science Daily

New molecule mimics the anti-clotting action of blood-sucking organisms

Nature gave ticks, mosquitoes and leaches a quick-acting way to keep blood from clotting while they extract their meal from a host. Now the key to that method has been harnessed by a team of researchers as a potential anti-clotting agent that could be used as an alternative to heparin during angioplasty, dialysis care, surgeries and other procedures. Nature gave ticks, mosquitoes and leaches a quick-acting way to keep blood from clotting while they extract their meal from a host. Now the key to that method has been harnessed by a team of Duke researchers as a potential anti-clotting agent that could be used as an alternative to heparin during angioplasty, dialysis care, surgeries and other procedures. Publishing in the journal Nature Communications, the researchers describe a synthetic molecule that mimics the effects of compounds in the saliva of blood-sucking critters. Importantly, the new molecule can also be swiftly reversed, enabling clotting to resume when needed after treatment. "Biology and evolution figured out anti-coagulation multiple times with a highly potent strategy," said senior author Bruce Sullenger, Ph.D., professor in the departments of Surgery, Cell Biology, Neurosurgery and Pharmacology & Cancer Biology at Duke University School of Medicine. "It's the perfect model." Sullenger and colleagues at Duke and the University of Pennsylvania -- including lead author Haixiang Yu, Ph.D., a member of Sullenger's lab -- started from the observation that all blood-sucking organisms evolved a similar system to inhibit blood clotting. The anti-clotting agent in their saliva uses a two-pronged process, binding to the surface of certain clotting proteins in the host's blood, and entering into the protein's core to temporarily inactivate clotting during a blood meal. Blood-sucking organisms target different proteins among the sequence of more than two dozen molecules involved in clotting, but the research team concentrated on engineering molecules to home in on thrombin and factor Xa in human blood, achieving the dual-action anti-clotting function against these proteins. The next challenge was devising a way to reverse the process -- essential for clinical applications to ensure that people don't hemorrhage. With the activation mechanism fully elucidated, the researchers were able to reverse engineer an antidote that quickly restores clotting. "We believe this approach could be safer for patients and generate less inflammation, as well," Yu said. Another plus is that it is a synthetic molecule, unlike the current clinical standard for the past 100 years, heparin. Heparin is isolated from pig intestines, requiring a massive farming infrastructure that generates pollution and greenhouse gases. "This is part of a new passion of mine -- improving agents that control blood clotting to help patients, while also being responsible from a climate perspective," Sullenger said. "The medical field is starting to recognize that there's a big problem here, and we need to find alternatives to using animals for making medicines." In addition to Sullenger and Yu, study authors include Shekhar Kumar, James W. Frederiksen, Vladimir N. Kolyadko, George Pitoc, Juliana Layzer, Amy Yan, Rachel Rempel, Samuel Francis, and Sriram Krishnaswamy. The study received funding support from the National Institutes of Health (P01-HL139420, 23POST1018721). Duke has submitted a patent application on the thrombin and factor Xa EXACT inhibitors; Sullenger and Yu are listed as inventors.

2024-03-11

·BioSpace

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update - March 11, 2024

Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety pro first oral on-demand therapy for hereditary angioedema CEO transition supports ongoing evolution into commercial company CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2024. “This has been an exciting and busy period for KalVista, as we achieved key milestones with the release of our phase 3 KONFIDENT data and the completion of a substantial financing,” said Ben Palleiko, Chief Executive Officer of KalVista. “We remain on track to NDA with the U.S. Food and Drug Administration in the first half of this year, and we look forward to presenting further phase 3 data for sebetralstat at upcoming patient and medical meetings. We also continue to grow the commercial organization to enable us to deliver on the promise of providing the first oral, on-demand treatment option to the HAE community.” Third Fiscal Quarter and Recent Business Highlights: In February, the Company announced positive topline data from the Phase 3 KONFIDENT clinical trial evaluating the safety and efficacy of sebetralstat as the potential first oral, on-demand therapy for hereditary angioedema (HAE). KONFIDENT was the largest and most representative trial ever conducted in HAE, enrolling a total of 136 patients from 66 clinical sites across 20 countries. Eligible participants included adolescents, patients using long-term prophylaxis, and the trial evaluated all attack severities and locations. The clinical trial met all primary and key secondary endpoints across both the 300 and 600 mg doses and demonstrated a safety pro to placebo. Also in February, KalVista closed an underwritten offering to sell an aggregate of 7,016,312 shares of common stock at price of $15.25 per share and pre-funded warrants to purchase up to 3,483,688 shares of common stock at a price of $15.249 per pre-funded warrant. The net proceeds from the offering were approximately $150.1 million and are expected to provide funding into 2026. The Company announced that Benjamin L. Palleiko, the Company’s prior President, CBO and CFO, was appointed as Chief Executive Officer and a director of the Company. This appointment is the result of a planned transition as KalVista prepares to become a commercial entity following the success of the KONFIDENT Phase 3 trial for its program sebetralstat. The UK Medicines and Healthcare products Regulatory Agency (MHRA) awarded the Innovation Passport for sebetralstat, providing entry to the UK Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market and facilitate patient access to innovative medicines. Presented additional Phase 3 KONFIDENT data as well as data on unmet need in HAE from a patient perspective at the 2024 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) in Washington, D.C. Announced publication of the first report of a potent and specific Factor XIIa inhibitor with high oral availability in a peer-reviewed journal. The Frontiers in Pharmacology article describes the pharmacology of a representative compound from KalVista’s portfolio of structurally diverse, oral Factor XII inhibitors. Third Fiscal Quarter Financial Results: Revenue: No revenue was recognized for the three months ended January 31, 2024, or January 31, 2023. R&D Expenses: Research and development expenses were $22.5 million for the three months ended January 31, 2024, compared to $20.1 million for the same period in the prior fiscal year. The increase in R&D expenses during the quarter primarily reflects the ongoing Phase 3 KONFIDENT and KONFIDENT-S trials. G&A Expenses: General and administrative expenses were $10.6 million for the three months ended January 31, 2024, compared to $6.9 million for the same period in the prior fiscal year. The increase in G&A expenses was primarily due to increases in employee-related expenses and commercial planning expenses. Net Loss: Net loss was $29.0 million, or $(0.84) per weighted average basic and diluted share, for the three months ended January 31, 2024, compared to net loss of $21.3 million, or $(0.75) per weighted average basic and diluted share for the same period in the prior fiscal year. The increase in net loss primarily resulted from the increase in operating expenses, primarily research and development. Cash Position: Cash, cash equivalents and marketable securities were $75.6 million as of January 31, 2024, compared to $149.4 million as of April 30, 2023. The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista disclosed positive phase 3 data for the KONFIDENT trial for its oral, on-demand therapy sebetralstat in February 2024. The Company anticipates submitting a new drug application to the U.S. Food and Drug Administration (FDA) for sebetralstat in the first half of 2024 and expects to approval in Europe and Japan later in 2024. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases. For more information about KalVista, please visit . Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates, our ability to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2023, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. KalVista Pharmaceuticals Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) (Unaudited) January 31, April 30, 2024 2023 Assets Current assets: Cash and cash equivalents $ 23,056 $ 56,238 Marketable securities 52,530 93,137 Research and development tax credit receivable 23,011 16,568 Prepaid expenses and other current assets 5,506 6,383 Total current assets 104,103 172,326 Property and equipment, net 2,423 2,948 Right of use assets 7,045 7,822 Other assets 397 106 Total assets $ 113,968 $ 183,202 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 3,101 $ 4,817 Accrued expenses 14,840 9,128 Lease liability - current portion 1,187 1,087 Total current liabilities 19,128 15,032 Long-term liabilities: Lease liability - net of current portion 6,257 7,145 Total long-term liabilities 6,257 7,145 Stockholders’ equity: Common stock, $0.001 par value 34 34 Additional paid-in capital 516,920 507,133 Accumulated deficit (425,077 ) (343,082 ) Accumulated other comprehensive loss (3,294 ) (3,060 ) Total stockholders’ equity 88,583 161,025 Total liabilities and stockholders' equity $ 113,968 $ 183,202 KalVista Pharmaceuticals Inc. Condensed Consolidated Statement of Operations (in thousands, except share and per share amounts) (Unaudited) Three Months Ended Nine Months Ended January 31, January 31, 2024 2023 2024 2023 Revenue $ — $ — $ — $ — Operating expenses: Research and development 22,523 20,063 60,919 56,325 General and administrative 10,628 6,882 31,071 22,818 Total operating expenses 33,151 26,945 91,990 79,143 Operating loss (33,151 ) (26,945 ) (91,990 ) (79,143 ) Other income: Interest income 684 732 2,383 1,424 Foreign currency exchange rate gain (loss) 1,120 597 277 (237 ) Other income 2,319 4,313 7,335 11,354 Total other income 4,123 5,642 9,995 12,541 Net loss $ (29,028 ) $ (21,303 ) $ (81,995 ) $ (66,602 ) Net loss per share, basic and diluted $ (0.84 ) $ (0.75 ) $ (2.37 ) $ (2.58 ) Weighted average common shares outstanding, basic and diluted 34,723,379 28,278,453 34,567,853 25,810,369 KalVista Pharmaceuticals Inc. Condensed Consolidated Statements of Cash Flows (in thousands, unaudited) Nine Months Ended January 31, 2024 2023 Cash flows from operating activities Net loss $ (81,995 ) $ (66,602 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 597 530 Stock-based compensation expense 9,172 7,481 Realized (gain) loss from sale of marketable securities (1,130 ) 84 Non-cash operating lease expense (11 ) 52 Amortization of premium on marketable securities 88 890 Foreign currency exchange loss (gain) 596 (1,339 ) Changes in operating assets and liabilities: Research and development tax credit receivable (6,215 ) 2,049 Prepaid expenses and other current assets 906 4,440 Accounts payable (1,778 ) (1,911 ) Accrued expenses 5,644 1,701 Net cash used in operating activities (74,126 ) (52,625 ) Cash flows from investing activities Purchases of marketable securities (47,687 ) (63,757 ) Sales and maturities of marketable securities 89,475 112,509 Acquisition of property and equipment (27 ) (1,127 ) Website development costs (294 ) — Net cash provided by investing activities 41,467 47,625 Cash flows from financing activities Issuance of common stock from equity incentive plans 616 482 Issuance of common stock, net of offering expenses of $0.3 million — 56,582 Issuance of pre-funded warrants, net of offering expenses — 1,085 Net cash provided by financing activities 616 58,149 Effect of exchange rate changes on cash and cash equivalents (1,139 ) 1,168 Net (decrease) increase in cash and cash equivalents (33,182 ) 54,317 Cash and cash equivalents at beginning of period 56,238 30,732 Cash and cash equivalents at end of period $ 23,056 $ 85,049 View source version on businesswire.com: Contacts KalVista Pharmaceuticals, Inc. Jarrod Aldom Vice President, Corporate Communications (201) 705-0254 jarrod.aldom@kalvista.com Ryan Baker Head, Investor Relations (617) 771-5001 ryan.baker@kalvista.com Source: KalVista Pharmaceuticals, Inc. View this news release online at:

临床3期财报高管变更临床结果

2023-11-06

·PRNewswire

Global Antithrombotic/Anticoagulant Drugs Market Set to Reach $46.2 Billion by 2028 with a 7.9% CAGR

DUBLIN, Nov. 6, 2023 /PRNewswire/ -- The "Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global antithrombotic/anticoagulant drugs market is expected to reach $46.2 billion in 2028 from $31.6 billion in 2023 at a CAGR of 7.9%. This report discusses the implications of the trends mentioned above in the context of the current size and growth of the antithrombotic/anticoagulant drugs market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug categories and the country offers breakdowns of the antithrombotic/anticoagulant drugs market. Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the antithrombotic/anticoagulant drugs market. This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific, and the Rest of the World. For market estimates, data are provided for 2022 as the base year, forecasted through 2023-2028. Companies Mentioned Bayer AG Boehringer Ingelheim International GmbH Bristol Myers Squibb Daiichi Sankyo Co. Ltd. F. Hoffmann-La Roche Ltd. Johnson & Johnson Services Inc. Merck & Co. Inc. Pfizer Inc. Sanofi Report Includes 59 data tables and 35 additional tables Overview and an up-to-date analysis of the global markets for antithrombotic/anticoagulant drugs for the treatments of thrombotic (cardiovascular) disease Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028 Examination of the market potential for antithrombotic/anticoagulant drugs, and quantification of the global market for these drugs and its market segments and sub-segments over the next five years Estimate of the actual market size and revenue forecast for the market, and corresponding market share analysis based on product type, application and region In-depth information (facts and figures) pertaining to the market drivers, challenges, opportunities and prospects, as well as the technologies, regulatory scenarios and impact of COVID-19 A look at the major vendors in the global market for antithrombotic/anticoagulant drugs, and analysis of the healthcare industry structure, including market shares and recent mergers and acquisitions (M&A) activity Review of key patent grants and a look at breakthrough innovations, novel products, upcoming trends and technologies, and emerging applications for cardiovascular treatments Insight into the importance of ESG in the worldwide market, with a look at consumer attitudes, risks and opportunities assessment, and ESG practices followed by manufacturers and service providers Identification of the major stakeholders, and analysis of the competitive landscape based on recent developments, key financials and segmental revenues, and operational integration Profiles of the leading market players The following are the main conclusions reached in this report regarding antithrombotic and anticoagulant drugs: Recent innovations and the emergence of novel thrombin inhibitors have led to the decrease in revenue of traditional anticoagulants such as heparin and Vitamin K antagonists. Low molecular weight heparins, such as Fragmin (-11.8%) and Innohep (-14.1%), have seen a significant decrease in the market. The anticoagulant drug market will continue to grow at a slow rate compared to antiplatelet and thrombin inhibitors segment due to the lack of new drug launches since the expiration of the patent on Plavix. The anticoagulant segment is expected to decline soon as prices fall and the market for novel thrombin inhibitors grows. The market for thrombin inhibitors is expected to grow at the highest CAGR of 8.1% over the forecast period of 2023 to 2028. Xarelto (rivaroxaban), Eliquis (apixaban), TNKase (tenecteplase) and Savaysa (edoxaban) are the major contributors to the high growth rate of thrombin inhibitors. An aging population and the increased prevalence of cardiovascular disease worldwide fueled by a Westernized diet and lifestyle have created new opportunities for antithrombotic/ anticoagulant drug products. Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Market Outlook Market Summary Chapter 3 Market Overview Overview of Cardiovascular Disease Coronary Artery Disease Atherosclerosis Angina (Angina Pectoris) Acute Myocardial Infarction Medical Management Lifestyle Changes Diet Modification Smoking Cessation Pharmaceuticals Anticoagulants and Antiplatelet Drugs Major Drivers Coagulation Factors Targeted to Reduce Cvd The Global Burden of Cardiovascular Disease 2030 Global Burden of Cardiovascular Disease The Global Economic Burden of Cardiovascular Disease Sales Performance of Major Drugs in 2022 Chapter 4 Global Market for Anticoagulant Drugs Overview Products Low Molecular Weight Heparin Oral Anticoagulants (Vitamin K Antagonists) Global Anticoagulant Drugs Market Forecast Chapter 5 Global Market for Antiplatelet Drugs Overview Products Oral Antiplatelets Global Antiplatelet Drugs Market Forecast Chapter 6 Global Market for Thrombin Inhibitors Overview Products Direct Thrombin Inhibitors Thrombolytic Agents Direct Factor Xa Inhibitors Global Thrombin Inhibitors Market Forecast Chapter 7 Global Market for Antithrombotic/Anticoagulant Drugs by Region Overview North America Europe Asia-Pacific Rest of the World Chapter 8 Sustainability in the Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective Introduction to ESG Sustainability in Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective Key ESG Issues Consumer Attitudes Towards ESG Industry ESG Performance Analysis Case Study Concluding Remarks Chapter 9 Clinical Trials and Patent Landscape Clinical Trials Analysis Patent Analysis Patent by Assignee Chapter 10 M&A and Venture Funding Outlook Chapter 11 Competitive Landscape Chapter 12 Company Profiles Chapter 13 Appendix For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 项与 YG-001 相关的药物交易

登录后查看更多信息